Overview
Primary qualitative or quantitative defects of alpha-dystroglycan, often called dystroglycanopathies, are a group of rare genetic disorders that affect a protein called alpha-dystroglycan. This protein normally acts as a bridge connecting muscle cells to the surrounding tissue, and it also plays important roles in the brain and eyes. When alpha-dystroglycan does not work properly — either because there is not enough of it or because it is not built correctly — muscles become weak and may waste away over time. The brain and eyes can also be affected, leading to intellectual disability, seizures, and vision problems. These conditions range widely in severity. The most severe forms, such as Walker-Warburg syndrome and muscle-eye-brain disease, are present at birth and cause profound muscle weakness, brain malformations, and eye abnormalities. Milder forms, such as certain types of limb-girdle muscular dystrophy, may not appear until childhood or even adulthood and primarily cause progressive muscle weakness in the hips and shoulders. There is currently no cure for dystroglycanopathies. Treatment focuses on managing symptoms and improving quality of life. This includes physical therapy to maintain mobility, medications to control seizures, surgical interventions for eye or orthopedic problems, and supportive care for breathing and feeding difficulties. Research into gene therapy and other disease-modifying treatments is ongoing but still in early stages.
Key symptoms:
Muscle weakness, especially in the hips and shouldersDelayed motor milestones like sitting and walkingIntellectual disability or learning difficultiesSeizures or epilepsyEye abnormalities including nearsightedness and retinal problemsBrain malformations visible on MRIDifficulty breathingFeeding difficulties in infancyEnlarged calf muscles (pseudohypertrophy)Elevated creatine kinase levels in bloodJoint stiffness or contracturesScoliosis or curved spineDifficulty swallowingFloppy muscle tone in infancy (hypotonia)Progressive loss of ability to walk
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Variable
Can begin at different ages, from infancy through adulthood
Treatments
No FDA-approved treatments are currently listed for Primary qualitative or quantitative defects of alpha-dystroglycan.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Primary qualitative or quantitative defects of alpha-dystroglycan at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Primary qualitative or quantitative defects of alpha-dystroglycan.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Primary qualitative or quantitative defects of alpha-dystroglycan.
Community
No community posts yet. Be the first to share your experience with Primary qualitative or quantitative defects of alpha-dystroglycan.
Start the conversation →Latest news about Primary qualitative or quantitative defects of alpha-dystroglycan
No recent news articles for Primary qualitative or quantitative defects of alpha-dystroglycan.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What specific type of dystroglycanopathy does my child or family member have, and what gene is affected?,What is the expected course of this condition based on the specific subtype?,How often should we have follow-up appointments with the neuromuscular team, eye doctor, and other specialists?,Are there any clinical trials or research studies that we might be eligible for?,What therapies and interventions should we start now to maximize function?,When should we begin monitoring breathing and heart function?,What resources are available for educational support and family counseling?
Common questions about Primary qualitative or quantitative defects of alpha-dystroglycan
What is Primary qualitative or quantitative defects of alpha-dystroglycan?
Primary qualitative or quantitative defects of alpha-dystroglycan, often called dystroglycanopathies, are a group of rare genetic disorders that affect a protein called alpha-dystroglycan. This protein normally acts as a bridge connecting muscle cells to the surrounding tissue, and it also plays important roles in the brain and eyes. When alpha-dystroglycan does not work properly — either because there is not enough of it or because it is not built correctly — muscles become weak and may waste away over time. The brain and eyes can also be affected, leading to intellectual disability, seizures
How is Primary qualitative or quantitative defects of alpha-dystroglycan inherited?
Primary qualitative or quantitative defects of alpha-dystroglycan follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.